The Effect of Mtorc1 Inhibition on Nafld and Subsequent Hcc Development

Atsushi Umemura; Yoshio Itoh; Michael Karin

doi:10.1016/s0168-8278(16)01685-8

Related publications

Article2020

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

D Pfister, Nicole N Nunez, A Sinha, Assaf Weiner, A Deckowska, Matthias Pinter, Olivier Govaere, F Müller, Quentin M. Anstee, T Entgleitner, Roland Rad, Roser Pinyol, Sara Torrecilla, M Dudek, P Knolle, Angelika Weber, D Lengenhagger, Josep M. Llovet, Ido Amit, F Meissner, B Becher, M Heikenwälder

Zeitschrift für Gastroenterologie

Article2020

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

David Pfister, Natalia Fernández Núñez, Anindita Sinha, Assaf Weiner, Aleksandra Deczkowska, Matthias Pinter, Olivier Govaere, Felicitas Müller, Quentin M. Anstee, T Entgleitner, Roland Rad, Roser Pinyol, Sara Torrecilla, Michael Dudek, Percy A. Knolle, Amy Weber, D Lengenhagger, Josep M. Llovet, Ido Amit, Felix Meissner, Burkhard Becher, Mathias Heikenwälder

Zeitschrift für Gastroenterologie

Article2014

Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition

Atsushi Umemura, Eek Joong Park, Koji Taniguchi, Jun Hee Lee, Shabnam Shalapour, Mark A. Valasek, Mariam Aghajan, Hayato Nakagawa, Ekihiro Seki, Michael N. Hall, Michael Karin

Article2023

Effects of Early Life Oral Arsenic Exposure on Intestinal Tract Development and Lipid Homeostasis in Neonatal Mice: Implications for NAFLD Development

Junlai Liu, Christopher Benner, Michael Karin, Philip L.S.M. Gordts, Robert H. Tukey, Shujuan Chen, Xiaojing Yang, André Alberto Weber, Elvira Mennillo, Patrick Secrest, Max W. Chang, Samantha Wong, Sabrina Le

Article2022

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

Rohini Sharma, Anjana Pillai, Thomas U. Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, C.C. Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed O. Kaseb, Yi‐Hsiang Huang, Celina Ang, ,

The Effect of Mtorc1 Inhibition on Nafld and Subsequent Hcc Development

Discussion(0)

Related publications

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition

Effects of Early Life Oral Arsenic Exposure on Intestinal Tract Development and Lipid Homeostasis in Neonatal Mice: Implications for NAFLD Development

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC